Research programme: infectious disease vaccines - Marker Therapeutics Inc

Drug Profile

Research programme: infectious disease vaccines - Marker Therapeutics Inc

Alternative Names: Smallpox vaccine - Marker Therapeutics Inc; TPIV-300; TPIV-301

Latest Information Update: 24 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TapImmune
  • Developer Marker Therapeutics Inc; Mayo Clinic
  • Class Vaccines
  • Mechanism of Action Major histocompatibility complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Smallpox; Viral infections

Most Recent Events

  • 17 Oct 2018 TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc., while its subsidiary changed the name to Marker Cell Therapy
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Smallpox(Adjuvant therapy) in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections(Adjuvant therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top